Anti-CD48 Antibody is a humanized monoclonal antibody targeting CD48 (SLAMF2/BLAST-1). CD48 is a GPI-anchored cell surface glycoprotein belonging to the Signaling Lymphocyte Activation Molecule (SLAM) family, widely expressed on lymphocytes, monocytes, and endothelial cells. It serves as a high-affinity ligand for the NK cell receptor 2B4 (CD244) and the T cell receptor CD2, playing a role in mediating immune cell adhesion, activation, and co-stimulatory signaling. Research indicates that CD48 is highly expressed on the surface of hematologic malignancies such as multiple myeloma (MM). By specifically binding to CD48, Anti-CD48 Antibody not only blocks its interaction with ligands but also induces potent Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC), leading to direct tumor cell killing. It is a significant candidate tool for researching immunotherapy in hematological cancers.